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Abstract
We have investigated the morphology and transfection activity of cationic liposome-DNA complexes (CLDC) under
conditions relevant to both in vivo and in vitro studies. Moreover we have attempted to establish structure-function
relationships relevant for high transfection activities under both conditions. CLDC were composed of dimethyldioctade-
cylammonium bromide with either 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or cholesterol (Chol) interacting
either with pre-condensed DNA or with uncondensed plasmid DNA. Furthermore for steric stabilization 1% poly(ethylene
glycol)-phospholipid conjugate was added to CLDC containing Chol and plasmid DNA. The in vivo studies were carried out
in mice following i.v. injection, and the in vitro studies were performed on SK-BR-3 human breast cancer cells in the presence
of media with serum. The morphology of the CLDC, monitored by freeze-fracture electron microscopy, was investigated
after mixing with mouse serum or the medium where the cells were kept. The substitution of DOPE with Chol, and the
addition of N-[g-methoxypoly(oxyethylene)-K-oxycarbonyl-DSPE are producing CLDC which are stabilized with respect to
time and serum, and are relatively small (100^300 nm). These stabilized complexes show high expression of a marker gene in
mouse lungs reaching expression values up to 10 ng luciferase per mg tissue protein, but relatively low expression in SK-BR-3
cells in vitro. Additionally, some of the complexes containing pre-condensed DNA look like ‘map-pin’ structures showing
heads of the size of liposomes and short, stiff and tapering tails. The in vivo transfection activity of these preparations is
highest. Similar complexes containing DOPE rather than Chol as helper lipid precipitate in the presence of serum and
especially of cell medium and convert into hexagonal lipid (HII) phase. Such complexes, despite their high transfection
activity in vitro, show very little transfection activity in vivo. These comparisons may help us to understand the fundamental
difference between in vitro and in vivo activity of CLDC: high in vitro transfection activity seems to be associated with
hexagonal lipid precipitates whereas high in vivo activity seems to be related with small, stabilized complexes, which in our
case also exhibit some protrusions (map-pin structures). ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Many diseases have become a target for somatic
gene therapy, including acquired multifactorial dis-
eases such as cancer, arthritis and AIDS as well as
genetic disorders such as cystic ¢brosis and Duch-
enne muscular dystrophy [1^4]. Gene therapy meth-
ods have been designed to introduce genetic informa-
tion into patient’s cells to enable these cells to correct
or modulate a disease [5]. Over the past few years,
rapid progress has been made in controlling the in
vivo delivery and expression of therapeutic genes [6].
Presently, viral-based carriers of DNA are still the
most common method of gene delivery, although
there is a strong research e¡ort for developing syn-
thetic non-viral vectors, in particular, cationic lipo-
some-DNA complexes (CLDC) [7^9]. When com-
pared to viral vectors, liposomal gene delivery
systems o¡er several advantages, including the lack
of viral gene elements, low immunogenic and in£am-
matory responses, potential for transfer of expression
units of essentially unlimited size, and possibility for
cell-speci¢c targeting [10^12].
During the last 10 years, in vitro studies have dem-
onstrated convincingly that CLDC can mediate gene
delivery by showing relatively high expression of re-
porter genes in cultured cells [13^15]. Such prepara-
tions appeared initially to be ine¡ective for many in
vivo applications and showed instability in serum.
More recently, however, CLDC have also been
used for in vivo transfection in animals [16^21] as
well as in humans [22] by direct intra-tumoral injec-
tion [16], by repeated intravenous injection [17], by
aerosol inhalation [18] or administration to the nasal
epithelium [22]. Since initially CLDC have not been
as e⁄cient as viral vectors for achieving successful
gene transfer in vivo, much e¡ort has been devoted
in optimizing the complexes. This included synthesiz-
ing more e⁄cient cationic lipids [5,19,20], alternative
helper lipids [21,23], as well as plasmid expression
vectors [24], but also stabilization of the whole
CLDC by polyamines and poly(ethylene glycol)-
phospholipid conjugates [21]. With about 5.5 mg of
protein expressed per gram of packed cells in culture
[25] and more than 1 Wg protein expressed per gram
lung tissue [21,23,26] trans-gene expression levels
have recently approached those achievable with ad-
enovirus. Furthermore, there is growing awareness of
a discrepancy between in vivo and in vitro with re-
spect to transfection activity, and that screening and
optimization of CLDC must be done in vivo because
in vitro assays are usually not predictive [25].
Since 1993, there has been an increasing number of
publications describing the morphology of CLDC
[26^35]. These studies presented evidence for DNA-
induced fusion of the cationic lipid vesicles, but the
morphological result of this fusion process was vi-
sualized di¡erently, using such structural analogies
as ‘beads-on-string’ [27], oligolamellar particles
[26,29,32^34], bundled and folded loops of DNA
strands [35], and ‘spaghetti’-like ¢brils depicting
DNA coated by a lipid bilayer [28,31,36]. Hexago-
nally packed DNA, coated by lipid in the inverted
HII phase, was also proposed [30] and observed
under certain conditions [31]. Even particles adopting
the HI hexagonal tubular phase and containing the
DNA condensed in this tubular network, were ob-
served when starting with lipopolyamines instead of
cationic liposomes [37]. In most of these publications
it is claimed that a lipid coating is able to protect the
DNA from restriction enzymes or other degradative
processes [26^33], irrespective as to whether this coat
is made of a lipid bilayer sheet [27,29], tubule
[28,31,36], stacks [32,33], invaginated liposomes
[26], or non-bilayer lipid arrangements [30,31,37]. It
is also proposed that the lipid coat is able to enhance
the uptake of CLDC by recipient cells possibly via
endocytosis [36^40] and/or local fusion [36], and pos-
sibly help the escape of DNA material from the en-
dosomes into the cytoplasm [37^40].
Despite the increasing number of publications de-
scribing the morphology of CLDC, very little is
known about the transfection-active structure(s) re-
sponsible for in vitro and/or in vivo transfection ac-
tivity. Thus, in the present study, we have investi-
gated the morphology and the transfection activity
(in vitro and in vivo) of stabilized CLDC made of
plasmid DNA, dimethyldioctadecylammonium bro-
mide (DDAB), and cholesterol (Chol). Moreover,
we have compared both parameters (morphology
and transfection activity) with those obtained from
similar but non-stabilized complexes containing 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
instead of Chol. Morphological stability was studied
in bu¡er, culture media, and serum, with respect to
time. DDAB was chosen as ‘model’ compound out
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of 18 di¡erent cationic amphiphiles because DDAB/
Chol was one of the most e⁄cient vehicles for in vivo
gene delivery which were screened recently in mice
[21]. Furthermore, in a preliminary study with 1,2-
dioleoyl-3-trimethylammonium propane (DOTAP)
instead of DDAB we have obtained similar results
with respect to the e¡ect of Chol versus DOPE and
the relative di¡erences between in vitro and in vivo
activity.
2. Material and methods
2.1. Lipids and other reagents
DOPE and N-[g-methoxypoly(oxyethylene)-K-
oxycarbonyl-DSPE (PEG-PE) were purchased from
Avanti (Alabaster, AL). Puri¢ed Chol was obtained
from Calbiochem (San Diego, CA). Spermidine and
DDAB were purchased from Sigma (St. Louis, MO).
DDAB was recrystallized once from acetone-metha-
nol solution. D-Luciferin was obtained from Boeh-
ringer Mannheim. Chloroform solution of each lipid
was stored under argon in sealed ampules at 340‡C.
Other reagents of the highest possible grade were
purchased and used without further puri¢cation.
2.2. Preparation of liposomes
DDAB was mixed with DOPE or cholesterol in
1:1 molar ratio, and the solvent removed slowly
under reduced pressure at 50‡C on a rotary evapo-
rator. The dry lipid ¢lm was hydrated with 5% dex-
trose solution prewarmed to 50‡C and the container
was sealed under argon. The hydrated lipid suspen-
sion was sonicated in a bath sonicator (Lab Supplies,
Hicksville, NY) for 5^10 min at 50‡C. The ¢nal con-
centration of liposomes was 5 mM cationic lipid and
the size of liposomes was measured by dynamic light
scattering to be 195 þ 65 nm. Sonicated liposomes
were stored under argon at 4‡C until use.
2.3. Luciferase reporter system
Plasmid containing luciferase as a reporter gene
(pCMV/luc) was constructed with CMV promoter
[21]. Plasmids were puri¢ed using alkaline lysis pro-
cedures adopted and devised by Qiagen (Chatsworth,
CA). Plasmid purity was measured by the ratio of
absorbance at 260 nm vs. 280 nm, and puri¢ed plas-
mids were stored in bu¡er containing 10 mM Tris-Cl
and 1 mM EDTA at pH 8.0 at concentrations of
1^2 mg/ml.
2.4. Preparation of transfection complexes
Prior to the transfection experiments, the optimal
DNA/liposome ratio for forming complexes which
were not large aggregates was determined by mixing
a ¢xed amount of plasmid with various amounts of
liposomes as described in [21]. In general, the trans-
fection complexes were formed by pipetting the plas-
mid solution into a liposome suspension of equal
volume and mixing rapidly. The ¢nal DNA concen-
tration of the complexes was 200 Wg/ml for in vivo
studies and 10 Wg/ml for in vitro studies. Routinely,
liposomes containing 8^12 nmol of DDAB could
complex with 1 Wg plasmid without forming visible
large aggregates. Such complexes have excess positive
charge, but still tend to aggregate with time during
storage at 4‡C and lose transfection activity in 4
days. For in vitro experiments, which called for
more diluted complexes, CLDC at 5^12 nmol
DDAB per Wg DNA have been formed.
In order to prevent CLDC from forming large
aggregates and loosing their in vivo transfection ac-
tivity with time the following two stabilization meth-
ods were used, as described before [21]. Small
amounts of PEG-PE (from 0.5 to 2 mole percent of
cationic lipid) were added to the DNA-liposome
complexes within a few minutes after their prepara-
tion. Alternatively, the plasmid was partially con-
densed with spermidine (e.g. 0.5 nmole of spermidine
per Wg DNA) prior to mixing with the liposomes.
The optimal amount of spermidine was determined
by titrating the polyamine to DNA to a point before
forming large aggregates. Both PEG-PE and spermi-
dine were added as solutions in distilled water. The
size of the complexes was estimated by dynamic light
scattering (dLS) and freeze-fracture electron micro-
scopy (FFEM). The unmodi¢ed DDAB/Chol com-
plexes had average diameters of 388 þ 130 nm and
180 þ 120 nm respectively. The size of both types of
stabilized DDAB/Chol complexes was somewhat
smaller. The complexes stabilized by partial conden-
sation of DNA by spermidine showed the smallest
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size (293 þ 98 nm as measured by dLS and 140 þ 80
nm as measured by FFEM). Stabilization of the
complexes by PEG-PE as well as by spermidine
was performed only for the Chol containing com-
plexes. Further studies are required to establish the
e¡ect of such stabilization on DOPE-containing
complexes.
2.5. Assay of reporter gene expression
Puri¢ed luciferase was purchased from Boehringer
Mannheim as a standard for calibrating the lumin-
ometer and constructing a standard curve for the
relative speci¢c activity of luciferase. Reporter gene
expression in a tissue extract was presented in nano-
gram quantities of luciferase protein by converting
relative light units measured from a luminometer
into weight units according to a standard curve
[21]. Luciferase expressed in cells or tissues was ex-
tracted with cell lysis solution. E¡ective lysis bu¡er
consisted of 0.1 M potassium phosphate bu¡er at pH
7.8, 1% Triton X-100, 1 mM DTT and 2 mM EDTA.
2.6. In vivo delivery and gene expression
Female CD1 mice (4^6 weeks old, weighing ap-
prox. 25 g) were obtained from Charles River Labo-
ratory. In two sets of independent investigations with
three mice for every composition, each mouse re-
ceived 60 Wg CLDC at a concentration of 8 nmole
DDAB per Wg DNA by tail vein injection. Twenty-
four hours later they were euthanized and the anes-
thetized animals perfused with cold phosphate-buf-
fered saline (PBS) via heart puncture. Each tissue
was dissected and washed in PBS, and then homo-
genized in 6 ml round-bottomed culture tubes con-
taining 500 Wl of lysis bu¡er. The samples were kept
at room temperature for 20 min with occasional mix-
ing. The homogenized samples were centrifuged for
10 min at 3000 rpm in an Eppendorf centrifuge. Lu-
ciferase activity of each tissue was measured by mix-
ing 100 Wl of the reconstituted luciferase substrate
(Promega, Madison, WI) with 20 Wl of the superna-
tant of tissue homogenate in the injection system of a
luminometer. Peak light emission was measured for
10 s at 20‡C. Relative light units of each sample were
converted to the amount of luciferase in the tissue
extract were comparing with a standard curve which
was established for each set of experiments. The pro-
tein content of the extract was determined using pro-
tein assay kits (BioRad, Richmond, CA). Back-
ground was the count of corresponding lysis bu¡er
in tissues of mice without treatment. We have ob-
tained consistent negative controls of tissue samples
from mice that were treated with liposomes only or
with complexes with L-galactosidase DNA. The luci-
ferase activity of these tissues measured was at the
same level as lysis bu¡er analysis, i.e. 200^300 rela-
tive light units (RLU). After background subtrac-
tion, a standard curve was created to convert the
RLU into weight units which was linear from
2U102 to 9U106 RLU, which corresponded to
3U1035 ng up to 3 ng luciferase. According to this
standard curve the reporter gene expression in a tis-
sue extract was presented in nanogram quantities.
2.7. In vitro delivery and gene expression
SK-BR-3 cells were cultured in McCoy’s 5A me-
dium supplemented with 10% heat-inactivated bovine
calf serum and in 5% CO2 [21]. SK-BR-3 cells in
monolayer culture were plated at 50 000 cells per
well in 12-well plates and incubated overnight. In
more than three sets of independent investigations
with three wells per composition, each well received
1 Wg of pCMV/luc complexed with 8 nmole DDAB
within 20 min of complex formation. The complexes
were left in contact with the cells for 4 h at 37‡C.
Then they were removed and replaced by fresh me-
dium containing 10% serum. After 24 h of transfec-
tion the cells were lysed with 200 Wl per well of luci-
ferase lysis bu¡er. Luciferase activity after
transfection was determined as described above.
2.8. Freeze-fracture electron microscopy
For FFEM all CLDC were prepared under the
same conditions and using the same DNA (200 Wg/
ml) and lipid concentrations (8.0 nmole cationic lip-
id/1 Wg DNA) as described in Section 2.4 for the
transfection experiments. The CLDC were stored at
4‡C in dextrose bu¡er of low ionic strength. For ¢nal
incubation for 10 min CLDC suspensions were di-
luted 1:1 v/v either with 2-N-(morpholino)ethanesul-
fonic acid (MES) bu¡er (1.0 mM, pH 5.5), or mouse
serum (simulating in vivo conditions), or cell medium
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as well (RPMI-1640 with 10% fetal calf serum
(FCS); simulating in vitro conditions). Electron mi-
croscopical snapshots were taken after a storage time
of 3 days when all suspensions of the Chol-contain-
ing CLDC were still entirely clear and after 6 days
when the unmodi¢ed DDAB/Chol/DNA complexes
started to precipitate. For FFEM the samples were
quenched rapidly using the sandwich technique and
liquid propane (cooling rate s 104 K/s). The cryo-
¢xed specimens were fractured and shadowed with
Pt/C in a Balzers BAF 400D freeze-fracture device
at 3120‡C and 2U1036 torr. The cleaned replicas
were examined in a transmission electron microscope
(Zeiss CEM 902 A) [41].
3. Results
Preparations of CLDC are metastable with time
and since structural instability may be connected
with the loss of transfection activity, it is highly de-
sirable for in vivo applications to develop well-de-
¢ned formulations which are stable in bu¡er and in
serum over a reasonably long period of time. Stabi-
lization of cationic-plasmid DNA complexes was
achieved using Chol instead of DOPE, by addition
of PEG-PE, and also by pre-condensation of the
DNA by polyamines [21]. In order to study the in-
£uence of these stabilizing factors on the morphology
of CLDC, we investigated by FFEM the structure of
traditional DNA/DDAB/DOPE complexes and com-
pared their morphology with those of the newly de-
veloped CLDC stabilized by Chol, and additionally
either 1% PEG-PE, or spermidine-condensed plasmid
DNA. The morphology of all CLDC, whether non-
stabilized or stabilized, was investigated in bu¡er at
low ionic strength, cell medium, and mouse serum as
well.
C
Fig. 1. Morphology of CLDC (DDAB/DOPE/DNA). E¡ect of
mouse serum and culture medium. (A) Sample prepared and
stored in dextrose bu¡er, and diluted 50% v/v for ¢nal incuba-
tion at MES bu¡er (pH 5.5). (B) As in A, but incubated for
10 min in mouse serum, or (C) in cell medium. Some of the
lipidic particles at the fusion area of the complexes are marked
by arrows in A. In B hints for the formation of HII lipid phase
and in C areas with well-developed HII tubules are marked by
arrows. Bars on all freeze-fracture electron micrographs repre-
sent 100 nm and the shadow direction is running from bottom
to top.
BBAMEM 77447 24-9-98
B. Sternberg et al. / Biochimica et Biophysica Acta 1375 (1998) 23^35 27
3.1. Morphology and transfection activity of
DOPE-containing CLDC
DOPE is most commonly used as a helper lipid in
cationic liposome-mediated gene transfer [42].
Although an increased transfection potency of
DOPE-containing CLDC is described in most of
the in vitro studies, their in vivo transfection activity
is very low compared to Chol-containing CLDC
[21,23,26]. Because of these contrary reports we
undertook morphological analysis of CLDC contain-
ing DOPE and compared to similar complexes but
containing Chol.
The morphology of DNA/DDAB/DOPE com-
plexes is quite di¡erent compared to similar com-
plexes but containing Chol (shown below). This is
true in bu¡er (Fig. 1A), but especially in mouse se-
rum (Fig. 1B), as well as cell medium (Fig. 1C). Even
in bu¡er of low ionic strength (1.0 mM MES; pH
5.5) the liposomes fuse into larger aggregates after
interaction with the DNA, and have a tendency to
form non-bilayer structures such as lipidic particles.
Some of the lipidic particles at the fusion areas of the
liposomes are marked by arrows in Fig. 1A. This
tendency of DOPE-containing CLDC to form non-
bilayer structures such as the hexagonal (HII) lipid
phase is especially pronounced in mouse serum (Fig.
1B) and in cell medium (RPMI-1640, with 10% FCS)
at high ionic strength (Fig. 1C), where CLDC are
observed by FFEM as tightly packed, fused to bigger
units, and forming hexagonal (HII) lipid structures
(marked with arrows in Fig. 1B,C). No ¢brillar
structures of any type are observed. Interestingly,
these complexes show only 1% of the in vivo trans-
fection activity compared to the DDAB complexes
containing Chol. Contrary to the in vivo studies,
the in vitro transfection activity of the DOPE con-
taining complexes is very high (100%, Table 1).
3.2. Morphology of stabilized CLDC in low ionic
strength bu¡er
In contrast to non-stabilized DNA/DDAB com-
plexes containing DOPE, freeze-fracture electron mi-
crographs of similar complexes stabilized by Chol
(control) display small spherical particles (average
diameter in the range of 100^250 nm) with few pro-
trusions (marked by an arrow in Fig. 2A). This is
true for the clear suspension in bu¡er of low ionic
strength (1.0 mM MES; pH 5.5) and is still true after
3 days of storage time at 4‡C (Fig. 2A). Within a
storage time of 6 days, however, the suspension is
not clear any longer and the CLDC start to precip-
itate. The spherical particles obviously adhere, fuse,
and form larger complexes with diameters between
300 and 600 nm (Fig. 2B). In contrast, the morphol-
ogy of similar complexes but additionally stabilized
by PEG-PE is very similar to the 3 day old controls
even when the electron micrographs were taken from
6 day old samples, displaying still small spherical
Table 1
Luciferase expression in vitro (SK-BR-3 cells) and in vivo (mouse lung) by CLDC composed of DDAB/DOPE or DDAB/Chol and
DNA with or without stabilizing agents
Sample (age) Luciferase activity calculated as ng luciferase protein per mg tissue protein þ S.E.a
DDAB plus DOPE DDAB plus Chol DDAB/Chol plus either PEG-PE or spermidine
PEG-PE (1 mole% of DDAB) Spermidine (0.5 nmole/Wg DNA)
In vitro (freshly prepared) 79.17 þ 33.0 15.93 þ 3.6 ^ ^
(100 þ 41.2) (20.1 þ 4.5) ^ ^
In vivo (freshly prepared) 0.02 0.95 þ 0.29 0.52 þ 0.18 2.14 þ 1.75
(6 1) (100 þ 30.4) (55.1 þ 19.3) (224.6 þ 180.4)
In vivo (1 month old) ^ 0.0014 þ 0.0005 1.15 þ 0.66 4.14 þ 1.22
^ (6 1) (120.7 þ 70) (380 þ 128.0)
The in vitro data were obtained from more than three sets of independent experiments with three wells per composition within each
set, using SK-BR-3 cells in culture. The in vivo data are based on two sets of independent experiments with three mice per composi-
tion in each set, using i.v. injection and measuring luciferase expression in lungs. Procedures for both in vitro and in vivo measure-
ments as described in Section 2.
aNumbers in parentheses represent relative luciferase activity based on respective control values from [21] taken as 100% (DDAB/
DOPE for in vitro studies and DDAB/Chol for in vivo studies).
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Fig. 2. Morphology of CLDC (DDAB/Chol/DNA) in bu¡er. Additional stabilization by PEG-PE or spermidine. (A) Chol-stabilized
CLDC, 3 day old sample. Small complexes with some protrusions (marked by arrowheads) are observed. (B) Chol-stabilized CLDC, 6
day old sample. Much bigger aggregated/fused complexes without protrusions are observed. (C) Stabilized CLDC made with 1%
PEG-PE added. (D) Stabilized CLDC made with spermidine-condensed plasmid DNA. Both samples, shown in C and D, are 6 days
old, the additionally stabilized CLDC are quite small and show some short but sti¡er protrusions (marked by small arrows in C).
Some well-developed ‘map-pin’ structures, found at complexes where the plasmid DNA was pre-condensed by spermidine, are marked
by two arrows in D. All samples were prepared and kept in low ionic strength dextrose bu¡er and diluted 50% v/v before ¢nal incu-
bation with 1.0 mM MES bu¡er (pH 5.5). Bars on all freeze-fracture electron micrographs represent 100 nm and the shadow direction
is running from bottom to top.
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particles up to 300 nm in diameter and also showing
few protrusions (marked by an arrow in Fig. 2C).
Although 6 days old, DDAB/Chol complexes addi-
tionally stabilized by spermidine-condensed DNA
are even smaller, and show additionally few but
well developed, sti¡ and tapering protrusions
(‘map-pin’ structures; Fig. 2D). The map-pin struc-
tures of the complexes, as seen and marked by two
arrows in Fig. 2D, are characterized by spheroidal
heads showing diameters of one or two liposomes
(100^200 nm) and mainly short (about 200 nm) but
sometimes up to 600 nm long and tapering ‘pins’.
Both types of preparations additionally stabilized
by PEG-PE or by spermidine-condensed DNA are
clear and do not show any precipitation after storage
for months.
3.3. Morphology in serum or culture medium and
transfection activity of stabilized CLDC
We investigated the transfection activity both in
vivo and in vitro of plasmid DNA/DDAB/Chol com-
plexes as a control, and of similar but additionally
stabilized DDAB/Chol complexes either containing
1% PEG-PE and interacting with supercoiled plas-
mid DNA or without PEG-PE but interacting with
spermidine-condensed plasmid DNA. In parallel, we
have studied their morphology in serum as well as in
cell medium by FFEM. The in vivo studies were
carried out in mice following i.v. injection and there-
fore the morphology of the CLDC was investigated
in mouse serum. The in vitro transfection activity of
the CLDC was measured on SK-BR-3 cells and
therefore we studied their morphology in the same
medium where these cells were grown.
When examined in 50% mouse serum (10 min in-
cubation time), Chol-stabilized, 3 day old CLDC are
as small as they are in bu¡er at low ionic strength
(100^250 nm) but show very few protrusions (Fig.
3A). Such complexes show high transfection activity
in mouse lungs after i.v. injection (up to 3 ng expres-
sion per mg tissue protein) [21] and we take this level
of activity as 100% for further comparisons. After
the same incubation time in mouse serum, these
Chol-stabilized CLDC of the same composition but
6 days old, appear as densely packed aggregates of
spherical particles where the number of attached par-
ticles in each aggregate is quite high (approx. ten to
14; Fig. 3B). Such formulations have lost all their in
vivo transfection activity within 4 days [21]. Residual
¢brillar protrusions are not observed.
DDAB/Chol complexes additionally stabilized by
PEG-PE and incubated with mouse serum, are quite
small (approx. four to six attached particles) even
when 6 days old (Fig. 3C). Interestingly, these stabi-
lized complexes, freshly prepared, show about half of
the in vivo lung transfection activity (about 60%,
Table 1) observed with similar, freshly prepared com-
plexes but Chol-stabilized only (100%, standard val-
ue, Table 1). Freshly prepared DDAB/Chol com-
plexes where the DNA was pre-condensed by
spermidine showed even approx. 200% compared to
the Chol-stabilized, freshly prepared complexes (Ta-
ble 1). Interestingly, neither of these additionally sta-
bilized preparations loses activity within a storage
period of 6 days. In this case, the resulting complexes
are also quite small (approx. four to six attached
particles) even after 6 days storage time at 4‡C and
10 min incubation in serum, and additionally reveal
map-pin structures, marked by two arrows in Fig.
3D. It is remarkable that among the stabilized, 1
month old samples there were much higher expres-
sion rates (about 130% for PEG-PE stabilized com-
plexes and about 380% for complexes containing
spermidine-condensed DNA, Table 1) than for com-
plexes stabilized by Chol only, which, after the same
storage time, showed less than 20% of the standard
value (Table 1).
C
Fig. 3. Morphology of CLDC (DDAB/Chol/DNA) in mouse serum or culture medium. Additional stabilization by PEG-PE or sper-
midine. (A) Chol-stabilized CLDC, 3 day old sample, incubated in mouse serum for 10 min. (B) Chol-stabilized CLDC, sample 6
days old, incubated in mouse serum for 10 min. (C) Stabilized CLDC, incubated in mouse serum, made with 1% PEG-PE added. (D)
Stabilized CLDC made with spermidine-condensed plasmid DNA. ‘Map-pin’ structures, found at complexes where the plasmid DNA
was pre-condensed by spermidine and well preserved in mouse serum, are marked by two arrows in D. (E) Chol-stabilized CLDC, 6
day old sample, incubated in cell medium (RPMI-1640 with 10% FCS) for 10 min. All samples were prepared and stored as in Fig. 1,
and diluted 50% v/v with either mouse serum or culture medium before ¢nal incubation. Bars on all freeze-fracture electron micro-
graphs represent 100 nm and the shadow direction is running from bottom to top.
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When investigated after 10 min incubation in cell
medium (RPMI-1640, with 10% fetal calf serum
(FCS)), Chol-stabilized, 6 day old CLDC are quite
similar to those in mouse serum (aggregates of about
12 attached spherical particles), but packed looser
and showing no ¢brillar protrusions of any type
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(Fig. 3E). This is also true for DDAB/Chol com-
plexes additionally stabilized by PEG-PE as well as
by spermidine-condensed DNA (not shown here). In
contrast to their high in vivo transfection activity
(60^200%), their in vitro transfection activity is rela-
tively low, and shows less than 20% of luciferase
expression in SK-BR-3 cells compared to similar
but DOPE containing complexes, even when kept
in the same cell medium (Table 1).
4. Discussion
Complexes formed during interaction of cationic
liposomes with plasmid DNA display a variety of
polymorphic and metastable structures. These in-
clude small or large aggregates, of the two oppositely
charged macromolecular assemblies which maybe
loosely or tightly packed or fused [26^36,38,39], ¢-
brillar structures [28,31,36], and, last but not least,
inverted hexagonal HII-lipid arrangements [30,31].
They are metastable both with time [21] and in media
at high ionic strength, such as cell media and serum
[21,31,34,35]. Since structural instability seems to be
connected with loss of transfection activity, it is
highly desirable to develop well-de¢ned formulations
stable in bu¡er and in serum over a longer period of
time, a condition critical for in vivo applications [21].
Our structural investigations, using freeze-fracture
electron microscopy, show that stabilization of the
morphology of CLDC can be achieved by substitut-
ing Chol for DOPE as the helper lipid, by adding
poly(ethylene glycol)-phospholipid conjugates such
as PEG-PE shortly after complex formation, and
also by pre-condensation of the plasmid DNA by
polyamines such as spermidine. Whereas non-stabi-
lized complexes grow much larger during 6 days of
storage time even in bu¡er at low ionic strength (as
seen from Fig. 2B compared with Fig. 2A), the com-
plexes containing Chol and additionally stabilized by
PEG-PE as well as by spermidine maintain the same
morphology, displaying in both cases small-size com-
plexes (not bigger than 300 nm). In the case of stabi-
lization by PEG-PE, the protrusions connected with
the CLDC are relatively small (marked by an arrow
in Fig. 2C), while with spermidine stabilization they
are well developed and relatively big (pin of the map-
pin structures; marked by two arrows in Fig. 2D).
Non-stabilized CLDC made of DNA/DDAB and
containing DOPE show quite a di¡erent morphology
in bu¡er, serum as well as cell medium compared to
those containing Chol as helper lipid. After interac-
tion with DNA, the DDAB/DOPE liposomes fuse
into larger aggregates and show a clear tendency to
form non-bilayer structures [43,44] at a 1:1 molar
ratio of cationic amphiphile to helper lipid and
even in bu¡er of low ionic strength. FFEM is an
excellent technique to recognize and to distinguish
between non-bilayer structures such as hexagonal
HII phase [41], lipidic particles [28], or cubic phase.
Some of the lipidic particles formed during the fusion
process (marked by arrows in Fig. 1A) are decorat-
ing the fusion areas of the liposomes [28,31]. This
tendency to fuse into large extended aggregates,
thereby forming non-bilayer structures such as HII
lipid phases, is especially strong at high content of
DOPE [31,45] but also in media of high ionic
strength such as serum and cell medium (HII lipid
areas are marked by arrows in Fig. 1B,C) [45]. This
is also true for complexes containing cationic amphi-
philes other than DDAB as shown for 3L-[N-(NP,NP-
dimethylaminoethane)carbamoyl] cholesterol (DC-
Chol) in bu¡er at low ionic strength but high
DOPE:DC-Chol ratios (4:1 by mole) [31] or for DO-
TAP:DOPE at molar ratios of 1:1 and 1:2 but in
DMEM known for high ionic strength [45].
Interestingly, these large lipid precipitates, found
in mouse serum and extending here to areas of sev-
eral micrometers, show a much lower in vivo trans-
fection activity, only 1% of that shown by small
(100^300 nm), serum-stable DDAB complexes con-
taining Chol. However, these large extended lipid
precipitates, formed by DOPE-containing complexes
in cell medium, show very high transfection activity
in vitro (100%) compared to quite low in vitro activ-
ity (6 20%) of similar complexes containing Chol
instead of DOPE. Recent reports about high in vitro
transfection activity of complexes containing DOPE
in relation to their ability to form quite large com-
plexes in bu¡er of low ionic strength (400^1400 nm)
[38] or even non-bilayer structures such as cubic
phase [46] support our observations with DOPE-con-
taining complexes.
This discrepancy between high in vitro but low in
vivo transfection activity of similarly composed prep-
arations reveals a fundamental di¡erence between in
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vitro and in vivo gene delivery by means of CLDC.
Obviously, for in vitro transfection activity, large
extended hexagonal lipid arrays, precipitating the
DNA onto the cells in culture similarly to Ca3(PO4)2,
seem to be associated with high transfection rates.
Contrary to that, the in vivo transfection activity
seems to be highest with small complexes, stabilized
with respect to serum and time. It is possible that this
stabilization allows the complexed DNA to travel
within the blood stream avoiding immediate clear-
ance by the RES, and eventually to be adsorbed on
endothelial cells in lung capillaries where transfection
can occur.
Additional stabilization of Chol-containing CLDC
by addition of 1% of PEG does not change much the
morphology of freshly prepared complexes kept in
bu¡er at low ionic strength as seen by comparison
of Fig. 2A with Fig. 2C. However, pre-condensation
of the DNA has quite a remarkable e¡ect and leads
to the appearance of a new structure (the map pin),
characterized by spheroidal heads showing diameters
of one or two liposomes (100^200 nm) and mainly
short (about 200 nm) but sometimes up to 600 nm
long and tapering pins (Fig. 2D). These structures
are di¡erent from the spaghetti-like ¢brillar struc-
tures which are observed with CLDC made of
some other monovalent cationic amphiphiles and
DOPE at certain molar ratios, which represent a sin-
gle bilayer tube coating the supercoiled plasmid
DNA [28,31,36]. Interestingly, these pins do not
show normal fracture behavior when freeze-fracture
technique is applied [41]. They have a much thicker
diameter at their base (near the head) of about 30 nm.
It should be noted that condensation methods with
a variety of polycations such as spermidine have
been found to condense DNA molecules into toroids
or rods, whereby the rods show rather similar diam-
eters of 30 nm and lengths of 200^300 nm [9,47].
Therefore it is quite possible that the tapering pins
represent exposed, partly condensed DNA rods in-
teracting at one end with the CLDC. These map-pin
structures were also observed in mouse serum
although to a lesser extent (Fig. 3D), but not in
cell medium (not shown here). Therefore they seem
to be stable in serum but not in cell media.
Adding PEG-PE shortly after the complex forma-
tion, and also pre-condensation of the plasmid DNA
by spermidine, are e¡ective methods to stabilize ad-
ditionally both the morphology and the in vivo
transfection activity of CLDC made of DDAB/
Chol/DNA. Whereas DDAB/DNA complexes stabi-
lized by Chol alone, at the age of 1 day and incu-
bated with 50% mouse serum for 10 min, are still
small (100^200 nm; Fig. 3A) and show 100% in
vivo transfection activity (standard value, Table 1)
they form much bigger and tighter packed aggregates
with time (tight aggregates of ten to 14 spherical
particles after 6 days, Fig. 3B). Signi¢cantly, they
lose totally their in vivo transfection activity within
4 days [21]. Similar complexes when stabilized by the
methods described above are still quite small (aggre-
gates of four to six particles) even when 6 days old
and when incubated with 50% serum for 10 min (Fig.
3C,D). These preparations were functionally stable
for a month at 4‡C and gave reproducibly high
transfection activity in vivo after i.v. injection in
mice [21]. Interestingly, preparations additionally sta-
bilized by pre-condensing the DNA, which show
some serum-stable map-pin structures (Fig. 3D), ex-
hibit even higher gene expression in mice lungs (ap-
prox. 200%) than PEG-PE stabilized complexes (ap-
prox. 60%) which are not showing any protrusions in
serum (Fig. 3C).
When incubated with cell medium (RPMI-1640
containing 10% FCS), aggregates of about 12 spher-
ical particles (fairly tightly packed) are observed with
6 day old preparations whether Chol-stabilized (Fig.
3E) or additionally stabilized by either method de-
scribed above (not shown). The transfection activity
of all stabilized preparations in vitro with SK-BR-3
cells when kept in the same medium is quite low and
less than 20% of the activity of the same complexes
containing DOPE instead of Chol. This discrepancy
between high transfection activity in vivo but low in
vitro for similarly composed preparations is indica-
tive again of the di¡erent parameters involved in the
transfection process of cells under in vivo or in vitro
conditions. Parameters such as clearance rate of the
CLDC, their removal by the RES system, and their
reactivity with cells of the endothelial barrier [48] are
certainly essential for in vivo applications but are
irrelevant for in vitro transfection [37^40]. Our re-
sults also show clearly that screening for in vivo op-
timization of stabilized CLDC must be done with in
vivo assays, because in vitro assays can introduce
irrelevant and ine¡ective parameters [25].
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It appears from our studies that small, stabilized,
spherical particles (100^300 nm), forming only small
aggregates of a few particles in serum, even after
storage in bu¡er at 4‡C for 6 days, correlate with
the high luciferase expression observed in mouse
lungs. Although much smaller, these stabilized par-
ticles might have some similarity to recently de-
scribed heterogeneous particles in the shape of £at,
concentric, bent or amorphous stacks of bilayers in
the size range of 200^500 nm [32] or birefringent
liquid-crystalline condensed globules with sizes in
the order of 1000 nm [33]. Freshly prepared and in-
vestigated in bu¡er at low ionic strength, these struc-
tures appear as particles/globules with a short-range
lamellar order in which 2D layers of oriented DNA
are sandwiched between lipid bilayers being apart
from each other with an interlayer spacing of
6.5 nm [32,33]. However, in both publications no
activity was reported for the heterogeneous, mainly
quite big, oligolamellar particles. In contrast, a very
recent publication has reported the enhanced expres-
sion of chloramphenicol acetyltransferase gene in
most tissues examined using a homogeneous popula-
tion of DNA-liposome complexes between 200 and
450 nm in size, whereby the liposomes contributing
to the complexes showed an invaginated morphology
[26]. Whether or not invaginated liposomes or a
regular ¢ne structure of 2D DNA layers sandwiched
between lipid bilayers are also structural components
of the much smaller, stabilized, spherical particles
observed by us in serum, and whether these DNA-
lipid arrangements have some advantage for in vivo
gene expression are still open questions. Hexagonal
or cubic [46] non-bilayer DNA/lipid structures,
formed in samples containing DOPE instead of
Chol as helper lipid, can transfect very well in vitro.
Therefore, their lack of in vivo transfection activity is
due either to serum instability or a high clearance
rate.
Our investigations on DDAB/Chol/DNA com-
plexes show clearly that their in vivo transfection
activity is primarily related to small complexes, sta-
bilized with respect to serum and time. Similar re-
sults have also been obtained with DOTAP/Chol/
DNA complexes (unpublished results). Moreover,
we consider that the small protrusions as observed
in freshly prepared non-stabilized CLDC, and the
well-developed protrusions observed in stabilized
complexes including the map-pin structures revealed
by pre-condensing DNA, may contribute to their
high in vivo transfection activity. Based on these ob-
servations we believe that the stabilization of formu-
lation and morphology of the CLDC in biological
£uids is at least equally important for high transfec-
tion activity in vivo or in vitro as compared to the
speci¢c chemical nature of cationic amphiphiles.
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